$0.37
▲ +$0.01
(+1.37%)
Vol 5.8M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$717.5M
ROE
-118.8%
Margin
-354.4%
D/E
682.76
Beta
1.95
52W
$1–$4
Wall Street Consensus
16 analysts · Apr 20263
Strong Buy
7
Buy
5
Hold
1
Sell
0
Strong Sell
62.5%
Buy Rating
Price Chart
Similar Stocks
COYA
Coya Therapeutics Inc
$121.4M
QTTB
Q32 Bio Inc
$40.9M
PYXS
Pyxis Oncology Inc
$71.6M
RCEL
AVITA Medical Inc
$105.2M
MCRB
Seres Therapeutics Inc
P/E 25.0
$134.6M
HURA
TuHURA Biosciences Inc
$45.9M
ANIX
Anixa Biosciences Inc
$102.7M
ATYR
aTyr Pharma Inc
$76.7M
FBIO
Fortress Biotech Inc
P/E 28.5
$113.6M
GANX
Gain Therapeutics Inc
$123.8M
Earnings
Beat rate: 60.0%
Next Report
May 13, 2026
EPS Estimate: $-0.18
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.18 | — | — |
| Dec 2025 | $-0.20 | $-0.21 | $-0.01 |
| Sep 2025 | $-0.20 | $-0.21 | $-0.01 |
| Jun 2025 | $-0.18 | $-0.17 | +$0.01 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -117.8% | -117.8% | -117.8% | -118.8% | -118.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -333.1% | -344.8% | -344.8% | -344.8% | -354.4% | -354.4% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | — | 669.75 | 669.75 | 669.75 | 682.76 | 682.76 |
| Current Ratio | 4.40 | 4.40 | 4.40 | 4.40 | 3.28 | 3.28 |
Key Ratios
ROA (TTM)
-59.7%
P/S (TTM)
16.29
P/B
7.0
EPS (TTM)
$-0.69
CF/Share
$-1.55
52W High
$3.87
52W Low
$0.76
$0.76
52-Week Range
$3.87
How does GOSS compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
GOSS valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
16.3
▲
27%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
7.0
▲
183%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
GOSS profitability vs Biotechnology peers
ROE
-118.8%
▼
76%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-354.4%
▼
24%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-59.7%
▼
28%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
GOSS financial health vs Biotechnology peers
D/E ratio
682.8
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
3.3
▼
26%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
2.0
▲
101%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
GOSS fundamentals radar
GOSS
Peer median
Industry
GOSS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio